Details for Patent: 7,820,186

United States Patent 7,820,186: Scope, Claims, and Patent Landscape for Once-Daily Acne Gel (Adapalene + Benzoyl Peroxide + Specific Gelling System)

What does US 7,820,186 claim in concrete formulation terms?

US 7,820,186 is directed to a physiologically acceptable aqueous gel for once-daily treatment of common acne. The independent claim (claim 1) is composition-defined and locks in four formulation elements and three critical numeric ranges/quantities (all wt% of total aqueous gel composition).

Claim 1 elements (verbatim scope structure)

A physiologically acceptable aqueous gel composition for once-daily treatment of common acne that has:

1. Adapalene and/or pharmaceutically acceptable salts

   • 0.1% (wt%)

2. Dispersed benzoyl peroxide

   • 2.5% (wt%)

3. A specific gelling agent system

   • 4% acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80
   • 4% (wt%)
   • The gelling agent is not just “an acrylamide sodium acryloyldimethyltaurate copolymer” but the tandem system identified as a single composite:
     acrylamide sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80

4. Once-daily treatment requirement

   • Claim language ties the product to once-daily use (a use-claim limitation embedded in an article-of-manufacture style claim).

Claim 1 quantitative “lock points”

How is the scope constrained: what must be true for literal infringement?

Literal infringement of claim 1 (based on the text you provided) requires all of the following to be present as recited:

1. Product type: a physiologically acceptable aqueous gel
2. Indication/use: for common acne and once-daily treatment
3. Actives:
   • adapalene at 0.1% (or a pharmaceutically acceptable salt equivalent)
   • benzoyl peroxide at 2.5% in a dispersed form
4. Gelling system: exactly 4% of the composite described as
   acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80
   This is the most “design-around sensitive” aspect because it is not generic.

Design-around levers explicitly suggested by the claim structure

Given the numeric and identity constraints:

• Moving adapalene away from 0.1% (either lower or higher) breaks the “0.1%” requirement.
• Moving benzoyl peroxide away from 2.5% breaks the “2.5%” requirement.
• Replacing the gel system with a different gellant (even if it contains only one portion of the listed composite) risks falling outside “4% acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80.”
• Changing format from aqueous gel to a different carrier (cream, lotion, foam, hydroalcoholic gel, non-aqueous gel) risks noninfringement.
• Changing dosing from once daily could avoid the “once-daily treatment” limitation if it is treated as a real use limitation rather than an informational statement.

What is the claim’s likely breadth versus typical acne combo patents?

US 7,820,186 is narrower than many acne combination patents because it ties coverage to:

• exact wt% for each of three “locked” ingredients (0.1% adapalene, 2.5% benzoyl peroxide, 4% specific gelling system),
• a specific composite gellant identity with included excipients (isohexadecane and polysorbate 80 alongside the acrylamide sodium acryloyldimethyltaurate copolymer),
• and a once-daily administration framing.

That combination makes it closer to a formulation capture than a broad “adapalene + benzoyl peroxide in a gel” concept.

What adjacent drug-product space does this cover?

The claim targets a specific “triple lock” phenotype for acne therapy:

• Adapalene + benzoyl peroxide is a widely used acne pharmacology pairing, often sold as combination regimens or fixed combinations.
• The differentiator here is not the active pairing alone; it is the aqueous gel format and the specific gelling system amount and identity.

For landscape purposes, this means the patent’s commercial relevance will cluster around products that match all three of: 1) fixed adapalene 0.1% plus benzoyl peroxide 2.5%
2) a gel formulation
3) the specified acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80 at 4%

Any product that changes those ratios or substitutes the gelling system is structurally positioned to avoid literal capture.

How does the “once-daily” limitation shape landscape value?

Many acne products are marketed with specific dosing regimens. If a competitor product uses the same formulation but is labeled or instructed for twice-daily, the “once-daily treatment” element creates an additional axis for noninfringement arguments. Practically, this can force challengers to focus on:

• labeling and instructions tied to the claimed use,
• marketing claims and prescribing information,
• and whether the accused product is actually used according to the once-daily scheme.

Conversely, a product that is once daily and matches all formulation numbers will sit directly inside the claim’s core capture.

What other claims likely exist, and how do they affect enforceability?

You provided only claim 1. Without the remaining claims’ text, enforceability assessment across dependent claims (narrowing features, alternate gelling agent concentrations, alternative concentration ranges, additional excipients, processing steps, particle size definitions for “dispersed” benzoyl peroxide) cannot be mapped precisely.

Where does US 7,820,186 sit in the typical patent landscape for acne fixed combinations?

In an acne fixed-combination landscape, patents often fall into three overlapping buckets:

1. API combination selection and ratios
2. Formulation architecture (gel/cream/emulsion; rheology; solvent system; stability)
3. Dosing and use conditions (once daily versus twice daily; treatment schedules)

US 7,820,186’s claim 1 indicates it belongs primarily to bucket (2) and partially bucket (3), because while the API pair is defined, the claim’s uniqueness is the specific gelling system and the exact concentrations.

What does the claim imply about stability and formulation rationale (without expanding beyond claim scope)?

The claim requires a physiologically acceptable aqueous gel with:

• benzoyl peroxide at 2.5% as a dispersed component, and
• a gelling system based on acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80 at 4%.

From a landscape standpoint, this suggests the patent is aimed at a formulation that achieves workable delivery in an aqueous gel matrix with a benzoyl peroxide dispersion and a defined rheology system.

How competitors can avoid literal scope based on claim structure

Competitors and formulators can consider the main literal “switches” built into claim 1:

• Switch active loading: move away from 0.1% adapalene or 2.5% benzoyl peroxide.
• Switch dispersion strategy: if “dispersed benzoyl peroxide” is contested by product microstructure or supplier specification, litigation can focus on how benzoyl peroxide is incorporated.
• Switch gel architecture: replace the gelling system with another polymer/gel matrix (even if it achieves similar viscosity).
• Switch dosing: label use for twice daily while keeping composition near match (still risk under doctrine of equivalents depending on jurisdiction and claim interpretation, but literal avoidance exists if “once daily” is a real limitation).

What is the commercial “hit list” for assessing potential infringement risk?

A practical landscape approach centered on this claim should focus on products that simultaneously meet all of the following:

• API pair: adapalene + benzoyl peroxide
• Concentrations: 0.1% adapalene and 2.5% benzoyl peroxide
• Dosage form: aqueous gel
• Rheology system: the specified 4% gelling composite
• Use: once-daily instructions

Products that match only the active combination but do not match the gelling system or concentrations fall outside claim 1’s literal scope.

Key Takeaways

• US 7,820,186 claim 1 is a strict formulation claim with fixed wt% requirements: 0.1% adapalene, 2.5% benzoyl peroxide (dispersed), and 4% of acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80 in a physiologically acceptable aqueous gel for once-daily treatment of common acne.
• The most infringement-sensitive element is the specific gelling agent composite at 4%, followed by the exact active concentrations.
• The once-daily treatment limitation adds a usage-based constraint that can matter for products with different labeling regimens.

FAQs

1) Is US 7,820,186 broader than “adapalene + benzoyl peroxide in a gel”?

No. Claim 1 is narrower because it requires exact concentrations and a specific gelling system identity and level.

2) What element most effectively supports a formulation design-around?

Changing the gelling agent system away from 4% acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80, while also avoiding the fixed active concentrations.

3) Does claim 1 cover adapalene salts?

Yes. Claim 1 includes adapalene and/or at least one pharmaceutically acceptable salt thereof, still constrained to 0.1%.

4) Does the claim cover any benzoyl peroxide formulation?

The claim requires 2.5% dispersed benzoyl peroxide, which can be material for how benzoyl peroxide is incorporated.

5) If a product matches the composition but is dosed twice daily, does claim 1 still apply?

The claim includes a once-daily treatment limitation, which can support noninfringement arguments where dosing differs.

References

[1] United States Patent US 7,820,186, claim 1 (as provided by the user).